A whole-animal platform to advance a clinical kinase inhibitor into new disease space
January 22nd, 2018 by Masahiro Sonoshita
A whole-animal platform to advance a clinical kinase inhibitor into new disease space
A whole-animal platform to advance a clinical kinase inhibitor into new disease space, Published online: 22 January 2018; doi:10.1038/nchembio.2556
Combining Drosophila genetics with chemistry and computation led to the development of novel kinase inhibitors based on the RAF-targeting drug sorafenib that reveal the RET oncogene as an enhancer of drug action and improve the therapeutic window in medullary thyroid carcinoma models.